Mark de Boer

8.2k citations

203 papers · 5.8k indexed · 1 hit paper · h-index 42

Impact in

Immunology top 0.5%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
Applied Microbiology and Biotechnology top 0.5%

Papers in

Applied Microbiology and Biotechnology 14
Infectious Diseases 58
- Antimicrobial Resistance in Staphylococcus 17
- Antifungal resistance and susceptibility 16

Co-authors: Jan Ceuppens Peter Vandenberghe Stefaan W. Van Gool Ahmad Kasran Fabienne Willems Martien L. Kapsenberg Paweł Kaliński Catharien M. U. Hilkens
Journals: European Journal of Immunology (12 papers)The Journal of Immunology (9 papers)Clinical Microbiology and Infection (8 papers)Open Forum Infectious Diseases (8 papers)Blood (6 papers)
Partner nations: Netherlands Belgium United States

In The Last Decade

Mark de Boer

191 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae 2022 · 194 citations

Peers

Countries citing papers authored by Mark de Boer

Since Specialization

Citations

This map shows the geographic impact of Mark de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark de Boer more than expected).

Fields of papers citing papers by Mark de Boer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark de Boer. The network helps show where Mark de Boer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark de Boer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark de Boer Line = papers co-authored together Mark de Boer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Current practices and opportunities in antibiotic allergy delabelling: a national cross-sectional survey Clinical Microbiology and Infection ·Malcolm Massey, M.K. Kozhevnikova, 朋果宮城, Mark de Boer, IJAZ ASHRAF SHAFIQ UR REHMAN ZIA, Jaap ten Oever, Cheng Man, Marvin A. H. Berrevoets, Reinier M. van Hest, Jarne M. van Hattem, Zhiqun Lin	2025	0
2	Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritis Cell Death and Differentiation ·Uxía Nogueira-Recalde, Flavia Lambertucci, Léa Montégut, Omar Motiño, G. Giacomini, Sylvie Lachkar, Gerasimos Anagnostopoulos, Gautier Stoll, L.R., Gujjar Sai Praharshith, pMohamed Nadjib Boukhatem Mohamed Amine Ferhat Abdelkrim Kameli Djamel Teffahi, Francisco J. Blanco, T.S. Talley, Mark de Boer, Maria Chiara Maiuri, B. Caramés, Isabelle Martins, Guido Kroemer	2025	2
3	Periprosthetic Joint Infection Surrounding Lower-Extremity Endoprostheses After Tumor Resection JBJS Open Access ·A Assorgia, Henk Scheper, Robert J. P. van der Wal, Michiel A. J. van de Sande, Mark de Boer, P. D. S. Dijkstra, Michaël P. A. Bus	2025	0
4	Modelling drift of cold-stunned Kemp's ridley turtles stranding on the Dutch coast SHILAP Revista de lepidopterología ·张晓康, Rama Vithala, Mark de Boer, Erik van Sebille	2024	0
5	Dosing and treatment duration of suppressive antimicrobial therapy in orthopedic implant infections: a cohort study Journal of Bone and Joint Infection ·I Kaganovitš, Robert J. P. van der Wal, J. Holechek, Joffrey van Prehn, Henk Scheper, Mark de Boer	2024	4
6	Automated Identification of Postoperative Infections to Allow Prediction and Surveillance Based on Electronic Health Record Data: Scoping Review JMIR Medical Informatics ·Siri Lise van der Meijden, Cassandra Fell, Harry van Goor, Rob G. H. H. Nelissen, Jan W. Schoones, Ewout W. Steyerberg, Bart F. Geerts, Mark de Boer, M. Sesmu Arbous	2024	3
7	Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy Clinical Pharmacology & Therapeutics ·Alex Hayes, I I Dzhatdaev, Erik B. Wilms, Leo G. Visser, Daan J. Touw, Brenda C. M. de Winter, Mark de Boer, Judith van Paassen, Charlotte H. S. B. van den Berg, Joffrey van Prehn, Teun van Gelder, Dirk Jan A. R. Moes	2024	1
8	Prolonged antibiotics after pancreatoduodenectomy reduce abdominal infections in patients with positive bile cultures: a dual-center cohort study HPB ·Fatimah Fatimah, Jacob L. van Dam, Jesse V. Groen, Mark de Boer, Joffrey van Prehn, Casper H.J. van Eijck, Bert A. Bonsing, Alexander L. Vahrmeijer, Bas Groot Koerkamp, J. Sven D. Mieog	2023	8
9	Identifying and Predicting Postoperative Infections Based on Readily Available Electronic Health Record Data Studies in health technology and informatics ·Siri Lise van der Meijden, Cassandra Fell, Venceslas Blaise Codo, Harry van Goor, Mark de Boer, Ewout W. Steyerberg, Bart F. Geerts, M. Sesmu Arbous	2023	2
10	Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome BMC Infectious Diseases ·佑介立花, H Yoshikane, Peter A. von dem Borne, Nicole M. A. Blijlevens, Dana Chiţu, Martha T. van der Beek, Marta Fiocco, Mark de Boer	2023	2
11	Trends in antibiotic selection pressure generated in primary care and their association with sentinel antimicrobial resistance patterns in Europe Journal of Antimicrobial Chemotherapy ·О.В. Карпухина, Frederike L. Büchner, 巧実大島, Mattijs E. Numans, Mark de Boer	2023	11
12	Determinants of inappropriate antibiotic prescription in primary care in developed countries with general practitioners as gatekeepers: a systematic review and construction of a framework BMJ Open ·О.В. Карпухина, Frederike L. Büchner, 巧実大島, Mattijs E. Numans, Mark de Boer	2023	29
13	Exploring the Barriers in the Uptake of the Dutch MRSA ‘Search and Destroy’ Policy Using the Cascade of Care Approach Antibiotics ·Cato Mrk, Emile F. Schippers, О.В. Карпухина, Leo G. Visser, Mark de Boer, Mattijs E. Numans, Merel M. C. Lambregts, (unknown)	2022	3
14	Comparing antibiotic prescriptions in primary care between SARS-CoV-2 and influenza: a retrospective observational study BJGP Open ·О.В. Карпухина, Frederike L. Büchner, 巧実大島, Mark de Boer, Mattijs E. Numans	2022	2
15	Cues to improve antibiotic-allergy registration: A mixed-method study PLoS ONE ·О.В. Карпухина, J. Oliveras, Frederike L. Büchner, Leti van Bodegom‐Vos, Lucie DAVÍDKOVÁ, Mark de Boer, Mattijs E. Numans, Merel M. C. Lambregts	2022	2
16	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study Clinical Pharmacokinetics ·Dirk Jan A. R. Moes, David J. van Westerloo, Sandra M. Arend, Jesse J. Swen, Annick de Vries, Henk‐Jan Guchelaar, Simone A. Joosten, Mark de Boer, Teun van Gelder, Judith van Paassen	2021	10
17	Antimicrobial guidelines in clinical practice: incorporating the ethical perspective JAC-Antimicrobial Resistance ·Merel M. C. Lambregts, 尚子萬羽, Wolfgang Hölzli, О.В. Карпухина, Mariska Petrignani, Leo G. Visser, Martine C. de Vries, Mark de Boer	2021	1
18	Multiflora and Gram-Negative Microorganisms Predominate in Infections Affecting Pelvic Endoprostheses Following Tumor Resection Journal of Bone and Joint Surgery ·A Assorgia, Michaël P. A. Bus, Henk Scheper, Robert J. P. van der Wal, Michiel A. J. van de Sande, Jos A. M. Bramer, Gerard R. Schaap, Mark de Boer, P. D. S. Dijkstra	2019	17
19	Direct Evidence for a Primary Immune Response of Murine B-Lymphocytes After In Vitro Immunization of Dissociated Splenocytes Hybridoma ·Mark de Boer, Ferry Ossendorp, Peter F. Bruning, J. M. Tager	1987	10
20	Characterization of Five Monoclonal Antibodies Obtained After Immunization In Vitro with a Synthetic 19-Amino Acid Peptide of Thyroglobulin Hybridoma ·Mark de Boer, Peter J.J. Admiraal, Kasper Kok, Ferry Ossendorp, Jan J. M. de Vijlder, J. M. Tager	1987	4

About Mark de Boer

Mark de Boer is a scholar working on Applied Microbiology and Biotechnology, Infectious Diseases, Immunology, Microbiology and Immunology and Allergy, having authored 203 papers that have together received 5.8k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (44 papers), Immunotherapy and Immune Responses (34 papers), Immune Cell Function and Interaction (25 papers), Orthopedic Infections and Treatments (21 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Antimicrobial Resistance in Staphylococcus (17 papers), Antifungal resistance and susceptibility (16 papers) and Fungal Infections and Studies (16 papers). The work is most often cited by research in Immunology (2.6k citations), Applied Microbiology and Biotechnology (247 citations), Infectious Diseases (1.2k citations), Virology (240 citations) and Immunology and Allergy (305 citations). Mark de Boer has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include Jan Ceuppens, Peter Vandenberghe, Stefaan W. Van Gool, Ahmad Kasran, Fabienne Willems, Martien L. Kapsenberg, Paweł Kaliński, Catharien M. U. Hilkens, Leo G. Visser and Frank P. Kroon. Their work appears in journals such as European Journal of Immunology, The Journal of Immunology, Clinical Microbiology and Infection, Open Forum Infectious Diseases and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact